NICE Recommends Kadcyla, Kyprolis and Rejects Besponsa Coverage

The U.K. is planning to move Roche’s Kadcyla (trastuzumab emtansine) into the NHS’s routine funding programs later this summer, following guidance from the National Institute for Health and Care Excellence and an agreement from Roche to lower the cost of the breast cancer treatment.
Source: International Pharmaceutical Regulatory Monitor